| Metric | FY2024 | FY2023 |
|---|---|---|
| Revenue | $64K-87.2% | $499K |
| Cost of goods sold | $6.7M+29.5% | $5.1M |
| Gross loss | -$6.6M-42.1% | -$4.6M |
| Research and development | $1.5M-79.9% | $7.4M |
| Sales and marketing | $990K-42.5% | $1.7M |
| General and administrative | $8.6M-39.9% | $14.4M |
| Loss on impairment of long-lived assets | $1.7M | — |
| Total operating expenses | $12.8M-45.6% | $23.5M |
| Loss from operations | -$19.4M+31.2% | -$28.2M |
| Interest income | $484K+9.7% | $441K |
| Change in fair value - warrant liability | $11.0M+427.0% | -$3.4M |
| Change in fair value - derivative liability | $6.7M+258.5% | -$4.3M |
| Unrealized gain (loss) on marketable securities | -$98K-145.5% | $216K |
| Realized gain on marketable securities | $1.3M+40.5% | $942K |
| Legal settlement | -$1.1M | — |
| Vendor settlement | -$648K | — |
| Other income (expense), net | -$39K | — |
| Total other income (expense), net | $17.6M+393.5% | -$6.0M |
| Net loss prior to provision for income taxes | -$1.8M+94.9% | -$34.2M |
| Net loss | -$1.8M+94.9% | -$34.2M |
| Dividends earned on Series H-7 convertible preferred stock | -$2.4M-247.5% | -$698K |
| Accretion of discounts to redemption value of Series H-7 convertible preferred stock | -$8.3M-107.4% | -$4.0M |
| Deemed dividend (Series H-5 warrants) | -$199K | — |
| Net loss attributable to common stockholders | -$12.4M+68.1% | -$39.0M |
| Net loss per share basic | -$2.02+75.3% | -$8.19 |
| Net loss per share diluted | -$2.02+75.3% | -$8.19 |
| Basic weighted average Common Stock outstanding | $6.2M+29.5% | $4.8M |
| Diluted weighted average Common Stock outstanding | $6.2M+29.5% | $4.8M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.